Originally published as JCO Early Release 10.1200/JCO.2005.06.090 on November 8 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farag, S. S. Articles by Bloomfield, C. D. Search for Related Content PubMed PubMed Citation Articles by Farag, S. S. Articles by Bloomfield, C. D. Social Bookmarking                            What's this?

Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study

From The Ohio State University, Columbus, OH; The Cancer and Leukemia Group B Statistical Center; Duke University, Durham; Wake Forest University, Winston-Salem, NC; Dana-Farber Cancer Institute, Boston, MA; University of Alabama at Birmingham, Birmingham, AL; North Shore University Hospital, Manhasset; Roswell Park Cancer Institute, Buffalo, NY; University of Maryland Cancer Center, Baltimore, MD; University of Chicago, Chicago, IL; and Wayne State University School of Medicine, Detroit, MI

Address reprint requests to Sherif S. Farag, MB, PhD, Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, A433A Starling-Loving Hall, 320 W Tenth Avenue, Columbus, OH 43210; e-mail: farag-1{at}medctr.osu.edu

PURPOSE: Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML).

PATIENTS AND METHODS: In 490 patients, induction included cytarabine and daunorubicin (AD) or cytarabine and escalated doses of daunorubicin and etoposide ± PSC-833 (ADE/ADEP). Intensification included one cycle of high-dose cytarabine (HDAC) followed by etoposide/cyclophosphamide and mitoxantrone/diaziquone (group I), three HDAC cycles (group II), four intermediate-dose cytarabine (IDAC) or HDAC cycles (group III), or one HDAC/etoposide cycle and autologous stem-cell transplantation (ASCT; group IV).

RESULTS: Of 350 patients receiving AD, 73% achieved complete remission (CR), compared with 82% of 140 receiving ADE/ADEP (P = .04). Splenomegaly was associated with a lower CR rate (P < .001), and ADE/ADEP, with a higher CR rate in younger patients (P = .005). The 5-year disease-free survival (DFS) rate was 28% each for intensification groups I and II, compared with 41% and 45% for groups III and IV, respectively (P = .02). The 5-year cumulative incidence of relapse (CIR) was 62% and 67% for groups I and II, respectively, compared with 54% and 44% for groups III and IV, respectively (P = .049). The type of postremission intensification remained significant for DFS and CIR in multivariable analysis.

CONCLUSION: In younger adults with normal cytogenetics AML, splenomegaly predicts a lower CR rate, and the postremission strategies of either four cycles of I/HDAC or one cycle of HDAC/etoposide followed by ASCT are associated with improved DFS and reduced relapse compared with therapies that include fewer cycles of cytarabine or no transplantation.

Supported in part by grants from the National Cancer Institute to the Cancer and Leukemia Group B (grant Nos. CA101140, CA31946, CA77658, CA33601, CA41287, CA47545, CA03927, CA47577, CA35279, and CA32291), grant No. CA16058, and the Coleman Leukemia Research Fund.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Ellis, R. Bernsen, H. Ali-Zadeh, J. Kristensen, U. Hedstrom, L. Poughias, M. Bresnik, A. Al-Essa, and D. A. Stevens A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever J. Med. Microbiol., November 1, 2009; 58(11): 1474 - 1485. [Abstract] [Full Text] [PDF]

				I. M. Borrello, H. I. Levitsky, W. Stock, D. Sher, L. Qin, D. J. DeAngelo, E. P. Alyea, R. M. Stone, L. E. Damon, C. A. Linker, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML) Blood, August 27, 2009; 114(9): 1736 - 1745. [Abstract] [Full Text] [PDF]

				L. Maurillo, F. Buccisano, M. I. Del Principe, G. Del Poeta, A. Spagnoli, P. Panetta, E. Ammatuna, B. Neri, L. Ottaviani, C. Sarlo, et al. Toward Optimization of Postremission Therapy for Residual Disease-Positive Patients With Acute Myeloid Leukemia J. Clin. Oncol., October 20, 2008; 26(30): 4944 - 4951. [Abstract] [Full Text] [PDF]

				R. K. Funk, T. J. Maxwell, M. Izumi, D. Edwin, F. Kreisel, T. J. Ley, J. M. Cheverud, and T. A. Graubert Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice Blood, August 15, 2008; 112(4): 1434 - 1442. [Abstract] [Full Text] [PDF]

				M. Ellis, B. al-Ramadi, M. Finkelman, U. Hedstrom, J. Kristensen, H. Ali-Zadeh, and L. Klingspor Assessment of the clinical utility of serial {beta}-D-glucan concentrations in patients with persistent neutropenic fever J. Med. Microbiol., March 1, 2008; 57(3): 287 - 295. [Abstract] [Full Text] [PDF]

				Y-B Yu, J-P Gau, J-Y You, H-H Chern, W-K Chau, C-H Tzeng, C-H Ho, and H-C Hsu Cost-effectiveness of postremission intensive therapy in patients with acute leukemia Ann. Onc., March 1, 2007; 18(3): 529 - 534. [Abstract] [Full Text] [PDF]

				K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood, January 15, 2007; 109(2): 431 - 448. [Abstract] [Full Text] [PDF]

				M. Ellis, C. Frampton, J. Joseph, H. Alizadeh, J. Kristensen, A. Hauggaard, and F. Shammas An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy. J. Med. Microbiol., October 1, 2006; 55(Pt 10): 1357 - 1365. [Abstract] [Full Text] [PDF]

				P. O. Iversen, D. R. Sorensen, K. J. Tronstad, O. A. Gudbrandsen, A. C. Rustan, R. K. Berge, and C. A. Drevon A bioactively modified Fatty Acid improves survival and impairs metastasis in preclinical models of acute leukemia. Clin. Cancer Res., June 1, 2006; 12(11): 3525 - 3531. [Abstract] [Full Text] [PDF]

				C. D. Bloomfield, K. Mrozek, and M. A. Caligiuri Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions. Clin. Cancer Res., June 1, 2006; 12(11): 3564s - 3571s. [Abstract] [Full Text] [PDF]

				C. Compton The cancer and leukemia group B pathology committee at 50. Clin. Cancer Res., June 1, 2006; 12(11): 3617s - 3621s. [Abstract] [Full Text] [PDF]

				K. Mrozek and C. D. Bloomfield Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia Hematology, January 1, 2006; 2006(1): 169 - 177. [Abstract] [Full Text] [PDF]

				G. Marcucci, C. D. Baldus, A. S. Ruppert, M. D. Radmacher, K. Mrozek, S. P. Whitman, J. E. Kolitz, C. G. Edwards, J. W. Vardiman, B. L. Powell, et al. Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study J. Clin. Oncol., December 20, 2005; 23(36): 9234 - 9242. [Abstract] [Full Text] [PDF]